Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Inhaled Corticosteroids (ICS) Medications – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Inhaled Corticosteroids (ICS) Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.
Respiratory care providers and pharmaceutical stakeholders face a persistent challenge: managing chronic airway inflammation in asthma and COPD patients while minimizing systemic steroid exposure. Inhaled Corticosteroids (ICS) address this by delivering anti-inflammatory agents directly to lung tissue, reducing exacerbations and improving lung function. This report analyzes key ICS molecules—including Fluticasone, Budesonide, and Mometasone—across device platforms and therapeutic applications, offering actionable insights for formulary decisions and market positioning.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4945864/inhaled-corticosteroids–ics–medications
Market Sizing and Growth Trajectory (2024-2031)
The global market for Inhaled Corticosteroids (ICS) Medications was estimated to be worth US$ 3403 million in 2024 and is forecast to a readjusted size of US$ 4335 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031. Inhaled corticosteroids (ICS) are prescription medications that help reduce inflammation in the lungs. They are typically used daily to prevent asthma attacks and are sometimes prescribed for chronic obstructive pulmonary disease (COPD) or other respiratory conditions. ICS medications are commonly delivered via dry powder inhalers, allowing targeted treatment in the airways while minimizing systemic side effects. Examples include Beclomethasone dipropionate (Qvar®), Budesonide (Pulmicort®), Ciclesonide (Alvesco®), Fluticasone (Arnuity®, Flovent®), and Mometasone (Asmanex®). In 2024, the global average price of Inhaled Corticosteroids (ICS) Medications is around USD 18.7 per unit, with total sales reaching approximately 182 million units.
Industry Deep-Dive: Manufacturing Differentiation (Discrete vs. Process)
The ICS supply chain reveals a critical distinction between discrete manufacturing (inhaler device assembly, dose metering, and packaging) and process manufacturing (API synthesis of corticosteroid molecules). Discrete manufacturing dominates device production—dry powder inhalers require precision-engineered components (dosing cups, breath-actuated mechanisms) assembled in cleanroom environments. Process manufacturing governs API production, where Budesonide and Fluticasone synthesis involves multi-step organic reactions requiring strict purity controls (>99.0%). This bifurcation creates supply chain vulnerabilities: a single API shortage (e.g., Mometasone furoate in Q1 2025) can disrupt multiple finished-dose products across GSK, Teva, and AstraZeneca.
Recent Industry Data (Last 6 Months)
- July 2025 (Projected): The FDA is expected to issue final guidance on interchangeable ICS products under the generic drug user fee amendments, potentially accelerating biosimilar-like competition for Fluticasone propionate.
- March 2025: The Global Initiative for Asthma (GINA) updated its strategy report, recommending low-dose ICS-formoterol as reliever therapy for mild asthma—shifting focus from rescue-only SABA to maintenance anti-inflammatory approaches.
- Market dynamic: China’s ICS market grew 8.7% YoY in 2024 (vs. global 3.6%), driven by Lunan Better Pharmaceutical and Jewim Pharmaceutical gaining provincial reimbursement listing for Budesonide suspension.
Typical User Cases and Technical Challenges
- Case 1 (Asthma – Pediatric): A London tertiary care center treated 340 children (ages 6–11) with moderate persistent asthma using Budesonide dry powder inhaler (200 mcg twice daily). After 12 weeks, 78% achieved well-controlled status (ACT score ≥20), with 94% device technique proficiency after video-assisted training—highlighting the importance of patient education for discrete inhalation maneuvers.
- Case 2 (COPD – Elderly with Comorbidities): A German pulmonology network prescribed Fluticasone furoate/vilanterol (FF/VI) combination to 1,050 COPD patients (GOLD Group D). At 24 weeks, exacerbation rates fell 34% versus baseline, but 9% developed oral candidiasis—a known technical limitation of ICS deposition in oropharyngeal tissues, mitigated by spacer devices or post-inhalation gargling protocols.
- Technical Hurdle: Lung deposition efficiency varies widely among ICS devices—from 12-15% for some dry powder inhalers to 35-40% for optimized designs. This variability affects real-world efficacy and complicates bioequivalence standards for generic entry.
Policy and Regulatory Update (2024-2025)
- The European Medicines Agency (EMA) finalized a revised guideline on clinical development of ICS for COPD (effective June 2025), requiring longer-term exacerbation data (≥12 months) for new product approvals.
- Japan’s NHI price revision (April 2025) reduced reimbursement for Ciclesonide by 5.6% while maintaining premiums for combination ICS-LABA products, incentivizing fixed-dose combination development.
独家观察 / Exclusive Insight: Industry Stratification by Molecule and Region
A clear stratification is emerging: Mature markets (US, EU, Japan) are shifting toward triple therapy (ICS+LABA+LAMA) and high-value molecules like Fluticasone furoate and Mometasone, which offer once-daily dosing and improved safety profiles. Emerging markets (India, China, Brazil) continue to drive volume growth for Beclomethasone and Budesonide suspension, with Cipla and Shanghai Pharmaceuticals competing on price ($12–15 per unit) versus branded products ($22–28 per unit). By 2028, premium ICS segments (novel molecules, digital inhaler integration) are projected to grow at 5.9% CAGR versus value segments at 2.8% CAGR, reshaping R&D pipelines toward patient-centric, adherence-enhancing delivery systems.
The Inhaled Corticosteroids (ICS) Medications market is segmented as below:
GSK
Chiesi Farmaceutici
Teva Pharmaceutical
Sumitomo Pharma
Cipla
Glenmark Pharmaceuticals
Orion Corporation
Bausch Health
Viatris
Novartis
Covis Pharma
Zentiva
AstraZeneca
Lunan Better Pharmaceutical
Jewim Pharmaceutical
Shanghai Pharmaceuticals
Zhejiang Xianjun Pharmaceutical
Anhui Wellman Pharmaceutical
Segment by Type
Beclomethasone Dipropionate
Budesonide
Ciclesonide
Fluticasone
Mometasone
Others
Segment by Application
Asthma
COPD
Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
